X
<

What Allergan's Latest Developments Tell Us

PART:
1 2 3 4 5 6 7
Part 2
What Allergan's Latest Developments Tell Us PART 2 OF 7

Assessing Allergan’s Quarterly Revenues

Allergan’s revenues

Allergan (AGN) has segregated its businesses into three segments: US Specialized Therapeutics, US General medicines, and International. The company reported revenues of $4.01 billion for 2Q17, representing an 8.8% rise over 2Q16, driven by the strong performance of key brands in specialized therapeutics as well as from the acquisition of new brands like LifeCell.

Assessing Allergan&#8217;s Quarterly Revenues

Interested in AGN? Don't miss the next report.

Receive e-mail alerts for new research on AGN

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

Estimates for 3Q17

Wall Street analysts estimate revenues of $4.05 billion for 3Q17, which would be 11.7% higher than its revenues of $3.62 billion in 3Q16. This growth is expected to be driven by strong sales of specialized therapeutics products as well as the inclusion of revenues from acquired brands.

Revenues in 2Q17

Allergan reported revenues of $4.01 billion in 2Q17, surpassing Wall Street analysts’ estimates of $3.95 billion, which was ~8.8% higher than its $3.68 billion in 2Q16. This growth in revenues was driven by the performance of the US Specialized Therapeutics portfolio as well as an increase in sales from international markets. Lower sales of general medicines in US markets negatively impacted revenue growth.

Allergan saw revenue growth from its inclusion of LifeCell’s products, but these were substantially offset by the divestiture of its generics business and Anda to Teva Pharmaceuticals (TEVA) in 2016.

Notably, the VanEck Vectors Biotech ETF (BBH) has 6.8% of its total assets in Allergan BBH also has 6.4% in Biogen (BIIB), 11.2% in Gilead Sciences (GILD), and 4.2% in Incyte (INCY).

X

Please select a profession that best describes you: